The approach to screening and diagnosis of gestational diabetes mellitus(GDM) around the world is disorderly. The protocols for diagnosis vary not only in-between countries, but also within countries. Furthermore, in any country, this disparity occurs in-between its hospitals and often exists within a single hospital. There are many reasons for these differences. There is the lack of an international consensus among preeminent health organizations(e.g., American College of Gynecologists and World Health Organization). Often there is a disagreement between the country's national diabetes organization, its local health society and its regional obstetric organization with each one recommending a different option for approaching GDM. Sometimes the causes for following an alternate approach are very obvious, e.g., a resource strapped hospital is unable to follow the ivory-tower demanding recommendation of its obstetric organization. But more often than not, the rationale for following or not following a guideline, or following different guideline within the same geographic area is without any perceivable explanation. This review is an attempt to understand the problems afflicting the screening and diagnosis of GDM globally. It traces the major temporal changes in the diagnostic criteria of(1) some respected health organizations; and(2) a few selected countries. With an understanding of the reasons for this disparity, a way forward can be found to reach the ultimate goal: a single global guideline for GDM followed worldwide.
展开▼
机译:Appropriate choice of stress modality in patients undergoing myocardial perfusion scintigraphy with a cardiac camera equipped with solid-state detectors: the role of diabetes mellitus
机译:2型糖尿病的治疗:艾塞那肽或利拉鲁肽? -艾塞那肽和利拉鲁肽的头对头比较大约相等[Behandlung des Diabetes mellitus Typ 2:艾塞那肽吗? -Exenatid und Liraglutid是“头对头”-Verwaich in etwa gleichrangig]